CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) General Counsel James Kasinger sold 1,990 shares of CRISPR Therapeutics stock in a transaction that occurred on Tuesday, October 6th. The shares were sold at an average price of $60.04, for a total transaction of $119,479.60. Following the sale, the general counsel directly owned 94,784 shares of the company’s stock, valued at $5,690,831.36. This represents a 2.06% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.
CRISPR Therapeutics Trading Down 3.6%
CRSP traded down $1.91 during trading on Thursday, hitting $50.44. 2,863,363 shares of the stock were exchanged, compared to its average volume of 1,757,269. The company has a debt-to-equity ratio of 0.34, a quick ratio of 17.85 and a current ratio of 17.85. The firm has a 50 day simple moving average of $54.99 and a 200 day simple moving average of $53.05. The firm has a market cap of $4.88 billion, a price-to-earnings ratio of -10.60 and a beta of 1.76. CRISPR Therapeutics AG has a 1 year low of $44.12 and a 1 year high of $78.38.
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) last announced its quarterly earnings results on Tuesday, June 30th. The company reported ($0.94) EPS for the quarter. The firm had revenue of $10.18 million for the quarter. CRISPR Therapeutics had a negative net margin of 3,368.72% and a negative return on equity of 24.39%. As a group, equities analysts expect that CRISPR Therapeutics AG will post -4.47 EPS for the current year.
Institutional Trading of CRISPR Therapeutics
Wall Street Analyst Weigh In
A number of analysts have weighed in on CRSP shares. Citizens Jmp restated a “market outperform” rating and set a $80.00 target price on shares of CRISPR Therapeutics in a report on Monday, August 31st. Wall Street Zen raised CRISPR Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Needham & Company LLC reiterated a “buy” rating and issued a $82.00 target price on shares of CRISPR Therapeutics in a research note on Monday, August 31st. Weiss Ratings reiterated a “sell (d-)” rating on shares of CRISPR Therapeutics in a report on Friday, July 17th. Finally, Morgan Stanley set a $60.00 price target on shares of CRISPR Therapeutics and gave the company an “equal weight” rating in a research report on Thursday, June 11th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $67.94.
Check Out Our Latest Analysis on CRSP
About CRISPR Therapeutics
CRISPR Therapeutics AG (NASDAQ: CRSP) is a biotechnology company focused on developing gene-editing medicines based on CRISPR/Cas9 technology. The company aims to treat serious diseases by precisely modifying genetic material in patients’ cells, with research programs spanning hematology, oncology, autoimmune diseases, and regenerative medicine.
Its lead product, CASGEVY (exagamglogene autotemcel), is a CRISPR/Cas9-based cell therapy developed with Vertex Pharmaceuticals. CASGEVY is approved in multiple markets, including the United States, United Kingdom, and European Union, for certain patients with sickle cell disease and transfusion-dependent beta thalassemia.
Featured Articles
- Five stocks we like better than CRISPR Therapeutics
- Want Private-Market Access to Kalshi and Polymarket? Try This ETF
- Levi’s Stock Dip Reveals Value Opportunity Despite Q3 Headwinds
- PepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value
- Alphabet’s $1.8 Billion Black Hills Deal Powers AI Data Center Push
Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
